Fig. 1.

Possible molecular mechanisms in endometriotic cells proliferation, survival, and progression towards malignancy. BAF BRM-associated factor, ARID1a/b AT-rich interactive domain-containing protein 1A/B, SMAR scaffold/matrix attachment region-binding protein 1, DPF1-3 zinc and double PHD fingers family 1 protein, ACTL6a/b actin-like protein 6A/B, GPCR G-protein-coupled receptors, GRB2 growth factor receptor-bound protein 2, RAS protein superfamily of small GTPases, Raf-1 proto-oncogene serine/threonine-protein kinase, TNF tumor necrosis factor, PI3K phosphoinositide 3-kinases, TAK1 mitogen-activated protein kinase kinase kinase 7, MAPK3 and ERK1/2 mitogen-activated protein kinase 3/2, MKK4/7 dual-specificity mitogen-activated protein kinase kinase 4/7, JIP1/2/3 JNK-interacting protein 1/2/3, JNKs(1–3) c-Jun N-terminal kinases (1–3), ATF2 activating transcription factor 2, p53 tumor protein p53, STAT3 signal transducer and activator of transcription 3, BAX Bcl-2-like protein 4, Bcl-2 B cell lymphoma 2, AKT protein kinase B, FOXO3 forkhead box O3, MEK1/2 mitogen-activated protein kinase kinase 1/2, ELK1 ETS like-1 protein Elk-1, ESR1 estrogen receptor 1, MITF microphthalmia-associated transcription factor, PAX6 paired box protein, cFos proto-oncogene, member of a bigger Fos family of transcription factors, ETS erythroblast transformation specific member, MYC MYC proto-oncogene, VEGF vascular endothelial growth factor, MNK mitogen-activated kinase, mTORC1/2 mammalian target of rapamycin complex 1/2, p7056K ribosomal protein S6 kinase beta-1, CAD carbamoyl-phosphate synthetase 2, SGK1 serum and glucocorticoid-regulated kinase 1, PKC protein kinase C, PTEN phosphatase and tensin homolog, PIP 2/3 phosphatidylinositol 4,5-bisphosphate/trisphosphate, PDK1 pyruvate dehydrogenase lipoamide kinase isozyme 1